Liposomal Sphingolipids to Target Breast Adenocarcinoma Apoptosis
Abstract
The purpose of these studies was to develop key data for the approach to the proof-of-principle, efficacy studies in Aim 5 using orthotopic Her-2/neu over-expressing human breast adenocarcinoma models. Investigations pertinent to Aims 1 (apoptosis), 2 (formulation) and 4 (toxicity) were initiated and are still ongoing. In two models examined to date, one model demonstrated interactions which were additive or greater between Wortmannin-mediated inhibition of the Akt/PKB pathway and sphingolipid induced apoptosis. These studies were in related ovarian cell lines and are presently being extended to human breast adenocarcinoma lines, with basal or high Her-2/neu expression. In formulation studies, we demonstrated that liposomes composed of 33 mole percent dimethyl-sphingosine (DMSp) and the balance of the lipids composed equivalently of dipalmitoyl-phosphatidyl choline and distearoyl-phosphatidyl choline, could be successfully formulated and that these were stable.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2000
- Accession Number
- ADA383846
Entities
People
- Jim Klostergaard
Organizations
- The University of Texas MD Anderson Cancer Center